The Ethical Committee of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, approved the study (reference number: 431/2016), and informed consent was obtained. Healthy volunteers were recruited from medical students and anesthesia residents from our hospital who were unaware of the study design and hypothesis (e.g., none of the authors of the present article acted as volunteer and none of the students or residents enrolled was involved in ventilation-related clinical research activities).
A custom-made system to deliver HFNC within a sealed Helmet connected to a water PEEP valve was developed (HFNC flow 50 L/min, temperature 31 8 C, external PEEP, 8 cm H 2 O; see Video E1 in the online supplement): HFNC (AIRVO 2, Fisher and Paykel Healthcare) was passed through an existing port in the lower part of a commercially available Helmet (StarMed CaStar Up, Intersurgical Ltd.) and sealed by an appropriate rubber gasket; the standard inlet port of the Helmet was closed and sealed, and respiratory tubing connected the expiratory port to a water PEEP valve.
Five healthy volunteers (study 1) were kept in a semirecumbent position, and a small-bore plastic tube was positioned through a sealed hole inside the HFNC 1 Helmet system, close to the mouth. Waveforms of airway pressure (Paw) inside the HFNC 1 Helmet were recorded on a computer for subsequent analysis by a dedicated system (Colligo, Elekton). FI O 2 was 0.30, flow 50 L/min, and temperature 31 8 C. Each subject underwent three study phases (random order, 15 min) at external PEEP of 3, 5, and 8 cm H 2 O. Toward the end, we measured vital signs, comfort (by a numeric 0-10 scale), mean Paw (Paw m ), and the average Paw excursion (DPaw) during the respiratory cycle.
Eight healthy volunteers (study 2) were kept in a semirecumbent position, and a small-bore plastic tube was advanced through a nostril to the hypopharynx. Waveforms of the CO 2 tension were recorded through this tube for 2-3 minutes at the end of each study phase ( (3, 4) .
Study sample size was chosen on the basis of previous studies (7, 8) . Given the small sample size, differences between variables across study phases were tested by one-way repeated measures ANOVA on ranks. Tukey test was used for post hoc correction (SigmaPlot 11.0, Systat Software Inc.).
Results
Paw m within the HFNC 1 Helmet system at three levels of external PEEP (3, 5, and 8 cm H 2 O) closely corresponded to the set PEEP level, and Paw oscillations during the respiratory cycle were very small ( Table 1 ), indicating that the HFNC 1 Helmet system effectively provides high, stable, and measurable PEEP. All the subjects tolerated the HFNC 1 Helmet system well at increasing PEEP levels (Table 1) .
PI CO 2 measured at the hypopharynx level was significantly higher during the standard Helmet phase than with HFNC and the HFNC 1 Helmet system, which had similar very low values (Table 2) . Respiratory rate and minute ventilation were significantly higher during the standard Helmet phase in comparison with HFNC and HFNC 1 Helmet, which were lower and similar (Table 2 ). PE CO 2 (i.e., the closest surrogate for arterial Author Contributions: T.M., E.S., A.P., and G.G., conceived and designed the study; T.M., E.S., M.M., A.G., C.D.P., E.C., D.T., and P.T. participated in acquisition and analysis of data for the study; T.M. and E.S. drafted the work; all authors collaborated to interpret data, revise the work critically for important intellectual content, and approve the version to be published; and T.M. and A.P. agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
This letter has an online video supplement, which is accessible from this issue's Table 2 ). The decrease in minute ventilation was mainly driven by a reduction in respiratory rate, whereas global and regional VT did not change significantly. End-expiratory lung volume, as assessed by DEELI, significantly increased during Helmet and HFNC 1 Helmet phases, globally, and in the dependent and nondependent lung regions, suggesting a homogenous distribution typical of healthy subjects. The increase in lung volume was similar between standard Helmet and HFNC 1 Helmet (Table 2) , once again indicating comparable PEEP level delivered by the two systems. Vital parameters and comfort remained stable with all three modes of respiratory support (Table 2) .
Discussion
The novel HFNC 1 Helmet system, delivering nasal high flow within a sealed Helmet connected to a PEEP valve, provides a clinically relevant, measurable, and stable PEEP. Moreover, the HFNC 1 Helmet system grants effective CO 2 washout from upper airways, with negligible CO 2 rebreathing and enhanced CO 2 clearance. Previous studies showed that increasing lung volume by standard Helmet (9) and lowering dead space by HFNC (10) might reduce the intubation rate of patients with acute hypoxemic respiratory failure (AHRF). Thus, the present studies generate the hypothesis that the combined HFNC 1 Helmet system may enhance our ability to avoid intubation and all the attendant risks of invasive mechanical ventilation in patients with AHRF.
The present studies have relevant limitations: they were performed in a small sample of healthy volunteers, and their results may not apply to patients with AHRF; key physiologic variables such as inspiratory effort and transpulmonary pressure were not investigated; study phases were short, and longer-term effects could differ (e.g., patients' comfort within the new HFNC 1 Helmet might be poorer than with standard HFNC limiting longterm application); in the clinical setting, HFNC 1 Helmet may mask signs of deteriorating respiratory function and delay intubation, yielding poorer clinical outcomes; previous studies (7, 8) showed that, when the fresh gas flow is set above 30 L/min, CO 2 rebreathing within the Helmet CPAP system might be negligible, and the new HFNC 1 Helmet system might be less useful.
In conclusion, the combination of HFNC 1 Helmet might present additive physiologic effects, potentially representing a new, noninvasive respiratory support. Further studies in patients with AHRF are needed to replicate the present findings and to assess the effects of HFNC 1 Helmet on arterial CO 2 tension (in hypercapnic patients) and on recruitment, oxygenation, and the respiratory drive (in hypoxemic patients). n
